Table 6.
Inhaled antineoplastics evaluated in clinics.
| Drug | Dose | Cancer Type | Reference |
|---|---|---|---|
| Gemcitabine | 1–4 mg/kg | NSCLC | [186] |
| Doxorrubicin | 0.4–9.4 mg/m2 | Primary and metastases in the lungs | [187] |
| 5-Fluorouracil | 250 mg | NSCLC | [188] |
| Carboplatin (iv or inhaled) +Docetaxel (iv) | Docetaxel: 100 mg/m2 Carboplatin: AUC 5.5 |
NSCLC | [189] |
| Liposomal cisplatin | 1.5–48 mg/m2 | NSCLC | [190] |
| Liposomal 9-Nitrocamptothecin | 6.7–26.6 µg/kg/day | Primary lung cancer Metastases in the lungs |
[191] |
Key: non-small cell lung cancer (NSCLC); intravenous (iv); area under the curve (AUC).